Once-A-Week Insulin Will Happen
Oct 10, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Alexandria Bartley, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences
The end to every day insulin use may be in sight.
Adherence to medications is usually tricky for patients with diabetes. Most people believe that a decrease in the number of injections in patients with a diabetes drug regimen will improve their compliance. Insulin icodec is the new once-weekly basal insulin analog and is under development to treat patients with diabetes. Insulin icodec could quickly improve glycemic control among patients with diabetes, as well as patients' adherence and acceptance. Previous data implied that patients with diabetes usually desire medication regimens with few injections and greater flexibility. Insulin icodec has a half-life of approximately one week and a peak of 16 hours. This trial is based on the conclusions in a phase 2 clinical trial that was aimed to research the efficacy and safety of once-weekly insulin icodec as compared with once-daily insulin glargine U100 in patients who had not received insulin previously and whose type 2 diabetes was inadequately controlled while on metformin with or without a dipeptidyl peptidase four inhibitor....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.